Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives
Published in: Leukemia & lymphoma
Access to document
10.1080/10428194.2025.2545927
document
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of 15 different neoplasms in adults. In Europe and North America, PTCL not otherwise specified (PTCL NOS), nodal T follicular helper lymphoma, angioimmunoblastic type (nTFHL-AI), and anaplastic large cell lymphoma (ALCL) either anaplastic lymphoma kinase (ALK) positive (+) or negative (-) are the most prevalent PTCLs. Relapsed or refractory disease (R/R) is common in PTCL and its management is challenging. Despite response rates and prognoses being disease specific, the outcome of R/R PTCL is dismal except for R/R ALK+ ALCL....
Frederik O Meeuwes, Yasmina I M Serroukh, Marjolein W M van der Poel, Wouter J Plattel, Marcel Nijland
Enteropathy-associated T-cell lymphoma: A population-based cohort study on incidence, treatment, and outcome in the Netherlands
Published in: EJHaem
Access to document
10.1002/jha2.1049
document
INTRODUCTION: Enteropathy-associated T-cell lymphoma (EATL) is a peripheral T-cell lymphoma (PTCL) with a poor prognosis. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide consolidated by autologous stem cell transplantation (ASCT) are recommended for fit PTCL patients. The role of etoposide and ASCT in EATL is unclear. METHODS: This study reports the incidence, treatment, and outcome of EATL patients using the Netherlands Cancer Registry, with nationwide coverage of >95%. RESULTS: All patients diagnosed in 1989-2021 (n = 351, 77% treated) were identified (median age 67 years, 56%...
Frederik O Meeuwes, Mirian Brink, Wouter J Plattel, Joost S P Vermaat, Marie José Kersten, Mariëlle Wondergem, Otto Visser, Marjolein W M van der Poel, Rimke Oostvogels, F J Sherida H Woei-A-Jin, Lara Böhmer, Tjeerd J F Snijders, Gerwin A Huls, Marcel Nijland
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Published in: Blood Neoplasia
Access to document
10.1016/j.bneo.2024.100023
document
Histiocytic disorders are rare hematologic neoplasms characterized by a notable dependence on mitogen-activated protein kinase signaling. Targeted therapy is an emerging treatment option, yet the number of reported patients remains limited. Here, we describe 40 patients with histiocytic neoplasms who were treated with targeted therapy in 7 tertiary referral hospitals from the Netherlands and Belgium. The cohort comprised of 6 (15%) children and 34 (85%) adults with diverse histiocytoses, including Langerhans cell histiocytosis (LCH; n = 12), Erdheim-Chester disease (n = 14), central nervous system xanthogranuloma (n =...
HOVON Histiocytic and Lymphocytic Diseases Working Group, Paul G Kemps, F J Sherida H Woei-A-Jin, Patrick Schöffski, Thomas Tousseyn, Isabelle Vanden Bempt, Friederike A G Meyer-Wentrup, Natasja Dors, Natasha K A van Eijkelenburg, Marijn A Scheijde-Vermeulen, Ingrid M Jazet, Maarten Limper, Margot Jak, Robert M Verdijk, Marjolein L Donker, Nick A de Jonge, Carel J M van Noesel, Konnie M Hebeda, Suzanne van Dorp, Sanne H ToninoJan A M van Laar, Cor van den Bos, Astrid G S van Halteren
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry
Published in: -
Access to document
10.1182/bloodadvances.2023012531
document
Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes in R/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK+) and ALK-negative (ALK-) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK+ ALCL, and ALK- ALCL (≥18 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The...
Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Reply to T. Vassilakopoulos et al
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.24.00143
document
Massimo Federico, Wouter Plattel, Martin Hutchings, Yana Stepanishyna, Catherine Fortpied, Marc André